Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2003 1
2004 1
2005 3
2006 1
2007 1
2008 4
2009 5
2010 2
2011 7
2012 12
2013 11
2014 20
2015 13
2016 12
2017 21
2018 20
2019 18
2020 25
2021 30
2022 36
2023 29
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

250 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Alzheimer's disease drug development pipeline: 2023.
Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Cummings J, et al. Alzheimers Dement (N Y). 2023 May 25;9(2):e12385. doi: 10.1002/trc2.12385. eCollection 2023 Apr-Jun. Alzheimers Dement (N Y). 2023. PMID: 37251912 Free PMC article. Review.
The Common Alzheimer's Disease Research Ontology (CADRO) was used to identify treatment targets and drug mechanisms. RESULTS: On the index date of January 1, 2023, there were 187 trials assessing 141 unique treatments for AD. ...DISCUSSION: The AD drug
The Common Alzheimer's Disease Research Ontology (CADRO) was used to identify treatment targets and drug mechanisms. RESULTS: …
Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review.
Di Lauro V, Barchiesi G, Martorana F, Zucchini G, Muratore M, Fontanella C, Arpino G, Del Mastro L, Giuliano M, Puglisi F, De Laurentiis M. Di Lauro V, et al. ESMO Open. 2022 Dec;7(6):100629. doi: 10.1016/j.esmoop.2022.100629. Epub 2022 Nov 16. ESMO Open. 2022. PMID: 36399953 Free PMC article. Review.
BACKGROUND: Evaluation of health-related quality of life (HR-QoL) among cancer patients has gained an increasing importance and is now a key determinant of anticancer treatments' value. HR-QoL has been assessed in trials testing cyclin-dependent kinase 4/6 in …
BACKGROUND: Evaluation of health-related quality of life (HR-QoL) among cancer patients has gained an increasing importance an …
A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials.
Sforzini L, Worrell C, Kose M, Anderson IM, Aouizerate B, Arolt V, Bauer M, Baune BT, Blier P, Cleare AJ, Cowen PJ, Dinan TG, Fagiolini A, Ferrier IN, Hegerl U, Krystal AD, Leboyer M, McAllister-Williams RH, McIntyre RS, Meyer-Lindenberg A, Miller AH, Nemeroff CB, Normann C, Nutt D, Pallanti S, Pani L, Penninx BWJH, Schatzberg AF, Shelton RC, Yatham LN, Young AH, Zahn R, Aislaitner G, Butlen-Ducuing F, Fletcher C, Haberkamp M, Laughren T, Mäntylä FL, Schruers K, Thomson A, Arteaga-Henríquez G, Benedetti F, Cash-Gibson L, Chae WR, De Smedt H, Gold SM, Hoogendijk WJG, Mondragón VJ, Maron E, Martynowicz J, Melloni E, Otte C, Perez-Fuentes G, Poletti S, Schmidt ME, van de Ketterij E, Woo K, Flossbach Y, Ramos-Quiroga JA, Savitz AJ, Pariante CM. Sforzini L, et al. Mol Psychiatry. 2022 Mar;27(3):1286-1299. doi: 10.1038/s41380-021-01381-x. Epub 2021 Dec 15. Mol Psychiatry. 2022. PMID: 34907394 Free PMC article. Review.
Criteria for treatment-resistant depression (TRD) and partially responsive depression (PRD) as subtypes of major depressive disorder (MDD) are not unequivocally defined. ...
Criteria for treatment-resistant depression (TRD) and partially responsive depression (PRD) as subtypes of major depressive disorder …
Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study.
Greenlee H, Iribarren C, Rana JS, Cheng R, Nguyen-Huynh M, Rillamas-Sun E, Shi Z, Laurent CA, Lee VS, Roh JM, Santiago-Torres M, Shen H, Hershman DL, Kushi LH, Neugebauer R, Kwan ML. Greenlee H, et al. J Clin Oncol. 2022 May 20;40(15):1647-1658. doi: 10.1200/JCO.21.01736. Epub 2022 Apr 6. J Clin Oncol. 2022. PMID: 35385342 Free PMC article.
PURPOSE: To examine cardiovascular disease (CVD) and mortality risk in women with breast cancer (BC) by cancer therapy received relative to women without BC. ...Cases with invasive BC diagnosed from 2005 to 2013 were matched 1:5 to controls without BC …
PURPOSE: To examine cardiovascular disease (CVD) and mortality risk in women with breast cancer (BC) by cancer thera
SynergyFinder 2.0: visual analytics of multi-drug combination synergies.
Ianevski A, Giri AK, Aittokallio T. Ianevski A, et al. Nucleic Acids Res. 2020 Jul 2;48(W1):W488-W493. doi: 10.1093/nar/gkaa216. Nucleic Acids Res. 2020. PMID: 32246720 Free PMC article.
SynergyFinder (https://synergyfinder.fimm.fi) is a stand-alone web-application for interactive analysis and visualization of drug combination screening data. Since its first release in 2017, SynergyFinder has become a widely used web-tool both for the discovery of n …
SynergyFinder (https://synergyfinder.fimm.fi) is a stand-alone web-application for interactive analysis and visualization of drug com …
An open-source drug discovery platform enables ultra-large virtual screens.
Gorgulla C, Boeszoermenyi A, Wang ZF, Fischer PD, Coote PW, Padmanabha Das KM, Malets YS, Radchenko DS, Moroz YS, Scott DA, Fackeldey K, Hoffmann M, Iavniuk I, Wagner G, Arthanari H. Gorgulla C, et al. Nature. 2020 Apr;580(7805):663-668. doi: 10.1038/s41586-020-2117-z. Epub 2020 Mar 9. Nature. 2020. PMID: 32152607 Free PMC article.
On average, an approved drug currently costs US$2-3 billion and takes more than 10 years to develop(1). ...However, despite the fact that large databases of compounds exist, the ability to carry out large-scale structure-based virtual screening on computer clusters in an a …
On average, an approved drug currently costs US$2-3 billion and takes more than 10 years to develop(1). ...However, despite the fact …
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.
DeMichele A, Cristofanilli M, Brufsky A, Liu X, Mardekian J, McRoy L, Layman RM, Emir B, Torres MA, Rugo HS, Finn RS. DeMichele A, et al. Breast Cancer Res. 2021 Mar 24;23(1):37. doi: 10.1186/s13058-021-01409-8. Breast Cancer Res. 2021. PMID: 33761995 Free PMC article.
This study examined the effectiveness of first-line palbociclib plus letrozole versus letrozole alone on survival outcomes in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-negative (HER2-) metastatic breast cancer (MBC) treated …
This study examined the effectiveness of first-line palbociclib plus letrozole versus letrozole alone on survival outcomes in patients with …
Automated discovery of drug treatment patterns for endocrine therapy of breast cancer within an electronic medical record.
Savova GK, Olson JE, Murphy SP, Cafourek VL, Couch FJ, Goetz MP, Ingle JN, Suman VJ, Chute CG, Weinshilboum RM. Savova GK, et al. J Am Med Inform Assoc. 2012 Jun;19(e1):e83-9. doi: 10.1136/amiajnl-2011-000295. Epub 2011 Dec 1. J Am Med Inform Assoc. 2012. PMID: 22140207 Free PMC article.
OBJECTIVE: To develop an algorithm for the discovery of drug treatment patterns for endocrine breast cancer therapy within an electronic medical record and to test the hypothesis that information extract …
OBJECTIVE: To develop an algorithm for the discovery of drug treatment patterns for endocrine breast
Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2- metastatic breast cancer.
Kristensen KB, Thomsen IMN, Berg T, Kodahl AR, Jensen AB. Kristensen KB, et al. Breast Cancer Res Treat. 2021 Aug;188(3):799-809. doi: 10.1007/s10549-021-06215-6. Epub 2021 Apr 10. Breast Cancer Res Treat. 2021. PMID: 33837869
PURPOSE: Treatment for estrogen receptor positive (ER+), human epidermal receptor 2 negative (HER2-) metastatic breast cancer (MBC) has improved with the approval of CDK 4/6 inhibitors. ...Data on tolerability and progression-free survival were collected from …
PURPOSE: Treatment for estrogen receptor positive (ER+), human epidermal receptor 2 negative (HER2-) metastatic breast canc
Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study.
Medas F, Dobrinja C, Al-Suhaimi EA, Altmeier J, Anajar S, Arikan AE, Azaryan I, Bains L, Basili G, Bolukbasi H, Bononi M, Borumandi F, Bozan MB, Brenta G, Brunaud L, Brunner M, Buemi A, Canu GL, Cappellacci F, Cartwright SB, Castells Fusté I, Cavalheiro B, Cavallaro G, Chala A, Chan SYB, Chaplin J, Cheema MS, Chiapponi C, Chiofalo MG, Chrysos E, D'Amore A, de Cillia M, De Crea C, de Manzini N, de Matos LL, De Pasquale L, Del Rio P, Demarchi MS, Dhiwakar M, Donatini G, Dora JM, D'Orazi V, Doulatram Gamgaram VK, Eismontas V, Kabiri EH, El Malki HO, Elzahaby I, Enciu O, Eskander A, Feroci F, Figueroa-Bohorquez D, Filis D, François G, Frías-Fernández P, Gamboa-Dominguez A, Genc V, Giordano D, Gómez-Pedraza A, Graceffa G, Griffin J, Guerreiro SC, Gupta K, Gupta KK, Gurrado A, Hajiioannou J, Hakala T, Harahap WA, Hargitai L, Hartl D, Hellmann A, Hlozek J, Hoang VT, Iacobone M, Innaro N, Ioannidis O, Jang JHI, Xavier-Junior JC, Jovanovic M, Kaderli RM, Kakamad F, Kaliszewski K, Karamanliev M, Katoh H, Košec A, Kovacevic B, Kowalski LP, Králik R, Yadav SK, Kumorová A, Lampridis S, Lasithiotakis K, Leclere JC, Leong EKF, Leow MK, Lim JY, Lino-Silva LS, Liu SYW, Llorach NP, Lombardi CP, Lóp… See abstract for full author list ➔ Medas F, et al. Lancet Diabetes Endocrinol. 2023 Jun;11(6):402-413. doi: 10.1016/S2213-8587(23)00094-3. Epub 2023 Apr 28. Lancet Diabetes Endocrinol. 2023. PMID: 37127041 Free PMC article.
BACKGROUND: Since its outbreak in early 2020, the COVID-19 pandemic has diverted resources from non-urgent and elective procedures, leading to diagnosis and treatment delays, with an increased number of neoplasms at advanced stages worldwide. ...METHODS: In this ret …
BACKGROUND: Since its outbreak in early 2020, the COVID-19 pandemic has diverted resources from non-urgent and elective procedures, leading …
250 results